[Treatment of normal pressure glaucoma with a serotonin S2 receptor antagonist, naftidrofuryl (praxilen)].
35 normal tension glaucoma patients were followed during 8 to 11 month. 12 patients received 2 x 200 mg/day Naftidrofuryl, a serotonine S2 receptor antagonist. As controles, another 23 patients were followed without treatment. The treated group, compared with the 23 non treated patients showed a significant increase in visual acuity (p = 0.001), a significant increase of the MS (p = 0.03), and a non significant decrease of the MD and CLV on the Octopus visual field (p, NS). The physiology and physiopathology of serotonine and S2 receptor antagonist are discussed.
Mermoud
A
A
Hôpital ophtalmique Jules Gonin, Lausanne.
Faggioni
R
R
D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D009257:Nafronyl / Q000008:administration & dosage*; D009883:Ophthalmic Solutions; D010865:Pilot Projects; D012702:Serotonin Antagonists; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
D009883:Ophthalmic Solutions; D012702:Serotonin Antagonists; D009257:Nafronyl
Le traitement du glaucome à pression normale avec un antagoniste des recepteurs S2 de la sérotonine, le naftidrofuryl (praxilen).